Literature DB >> 22454052

Bioinformatics and mutations leading to exon skipping.

F O Desmet1, C Béroud.   

Abstract

Our knowledge about human genes and the consequences of mutations leading to human genetic diseases has drastically improved over the last few years. It has been recognized that many mutations are indeed pathogenic because they impact the mRNA rather than the protein itself. With our better understanding of the very complex mechanism of splicing, various bioinformatics tools have been developed. They are now frequently used not only to search for sequence motifs corresponding to splicing signals (splice sites, branch points, ESE, and ESS) but also to predict the impact of mutations on these signals. We now need to address the impact of mutations that affect the splicing process, as their consequences could vary from the activation of cryptic signals to the skipping of one or multiple exons. Despite the major developments of the bioinformatics field coupled to experimental data generated on splicing, it is today still not possible to efficiently predict the consequences of mutations impacting splicing signals, especially to predict if they will lead to exon skipping or to cryptic splice site activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22454052     DOI: 10.1007/978-1-61779-767-5_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  Clinical evaluation and molecular screening of a large consecutive series of albino patients.

Authors:  Lucia Mauri; Emanuela Manfredini; Alessandra Del Longo; Emanuela Veniani; Manuela Scarcello; Roberta Terrana; Adriano Egidio Radaelli; Donata Calò; Giuseppe Mingoia; Antonella Rossetti; Giovanni Marsico; Marco Mazza; Giovanni Pietro Gesu; Maria Cristina Patrosso; Silvana Penco; Elena Piozzi; Paola Primignani
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

Review 2.  DNA variations in oculocutaneous albinism: an updated mutation list and current outstanding issues in molecular diagnostics.

Authors:  Dimitre R Simeonov; Xinjing Wang; Chen Wang; Yuri Sergeev; Monika Dolinska; Matthew Bower; Roxanne Fischer; David Winer; Genia Dubrovsky; Joan Z Balog; Marjan Huizing; Rachel Hart; Wadih M Zein; William A Gahl; Brian P Brooks; David R Adams
Journal:  Hum Mutat       Date:  2013-04-30       Impact factor: 4.878

3.  Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients' Cells.

Authors:  Florian Barthélémy; Cédric Blouin; Nicolas Wein; Vincent Mouly; Sébastien Courrier; Eugénie Dionnet; Virginie Kergourlay; Yves Mathieu; Luis Garcia; Gillian Butler-Browne; Christophe Lamaze; Nicolas Lévy; Martin Krahn; Marc Bartoli
Journal:  J Neuromuscul Dis       Date:  2015-09-02

4.  Dispelling myths about rare disease registry system development.

Authors:  Matthew Bellgard; Christophe Beroud; Kay Parkinson; Tess Harris; Segolene Ayme; Gareth Baynam; Tarun Weeramanthri; Hugh Dawkins; Adam Hunter
Journal:  Source Code Biol Med       Date:  2013-10-16

5.  Two novel tyrosinase (TYR) gene mutations with pathogenic impact on oculocutaneous albinism type 1 (OCA1).

Authors:  Vadieh Ghodsinejad Kalahroudi; Behnam Kamalidehghan; Ahoura Arasteh Kani; Omid Aryani; Mahdi Tondar; Fatemeh Ahmadipour; Lip Yong Chung; Massoud Houshmand
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

6.  A rapid and effective method for screening, sequencing and reporter verification of engineered frameshift mutations in zebrafish.

Authors:  Sergey V Prykhozhij; Shelby L Steele; Babak Razaghi; Jason N Berman
Journal:  Dis Model Mech       Date:  2017-03-09       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.